Serum IgG4 as a biomarker reflecting pathophysiology and post-operative recurrence in chronic rhinosinusitis

Oka, Aiko; Ninomiya, Takahiro; Fujiwara, Tazuko; Takao, Soshi; Sato, Yasuharu; Gion, Yuka; Minoura, Akira; Haruna, Shin ichi; Yoshida, Naohiro; Sakuma, Yasunori; Izuhara, Kenji; Ono, Junya; Taniguchi, Masami; Tamano, Haruna; Higaki, Toru; Kariya, Shin; Koyama, Takahisa; Takabayashi, Tetsuji; Imoto, Yoshimasa; Sakashita, Masafumi; Kidoguchi, Masanori; Nishizaki, Kazunori; Fujieda, Shigeharu; Okano, Mitsuhiro

doi:10.1016/j.alit.2019.12.004

Cited by 16 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study in the USA reported a mean follow-up of 4.4 years in 338 patients and a reoperation prevalence of 25% ( 29 ). A recent multicenter study in Japan showed a mean follow-up of 3.3 years and a recurrence prevalence of 23% in patients with CRSwNP ( 30 ). In recent years, precision medicine has been recognized increasingly as a direction to optimize the care of CRS patients.…”

Section: Discussionmentioning

confidence: 99%

Developments and Emerging Trends in the Global Treatment of Chronic Rhinosinusitis From 2001 to 2020: A Systematic Bibliometric Analysis

et al. 2022

View full text Add to dashboard Cite

BackgroundResearch on the treatment of chronic rhinosinusitis (CRS) has increased in recent decades. We undertook a bibliometric and visualization analysis of studies on CRS treatment to track research trends and highlight current research “hotspots”.MethodsOriginal publications related to CRS treatment were obtained from the Science Citation Index-Expanded (SCI-E) and Social Sciences Citation Index (SSCI) databases in the Web of Science Core Collection (WoSCC) of Clarivate Analytics between 2001 and 2020. The country/region, institution, author, journal, references, and keywords involved in this topic were extracted using CiteSpace and VOSviewer to identify and analyze the research focus and trends in this field.ResultsIn the previous two decades (especially after 2015), the number of publications on CRS treatment has grown markedly. With regard to publications and access to collaborative networks, the leading country was the USA. High-frequency keywords were “CRS,” “endoscopic sinus surgery,” “sinusitis,” “nasal polyps,” “asthma,” “rhinosinusitis,” “management,” “diagnosis,” “outcomes,” and “quality of life.” Inspection of keyword bursts suggested that “clinical practice guideline,” “adult CRS,” “innate lymphoid cell,” “recurrence,” and “mepolizumab” are the emerging research hotspots. The timeline view of the cluster map revealed that biologic agents have become an up-and-coming “hot topic” in CRS treatment in recent years.ConclusionAcademic understanding of CRS treatment has improved markedly over the past 20 years. We study analyzed the papers objectively, methodically, and comprehensively, and identified hotspots and prospective trends in the field of CRS treatment. These results will aid rhinologists in gaining greater insight into CRS treatment strategies and identifying the changing dynamics of CRS research.

show abstract

Section: Discussionmentioning

confidence: 99%

Developments and Emerging Trends in the Global Treatment of Chronic Rhinosinusitis From 2001 to 2020: A Systematic Bibliometric Analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Koyama et al [7] also reported positive correlation between the number of infiltrating IgG4-positive cells in tissues and serum IgG4 levels. In addition, Oka et al [14] recently showed that serum IgG4 level is higher in patients with moderate to severe ECRS than in those with mild to no ECRS. In the present study, local expression of IgG4 was high in EOM as well as in ECRS.…”

Section: Discussionmentioning

confidence: 99%

IgG4 Expression in Patients with Eosinophilic Otitis Media

Takahashi

Oka

Kariya

et al. 2021

ORL

Self Cite

View full text Add to dashboard Cite

Objective: Eosinophilic otitis media (EOM) is an intractable middle ear disease recognized by an eosinophil enriched middle ear effusion and mucosa. Although precise pathogenesis of EOM remains unclear, it is characterized by type 2 inflammation. Since IgG4 is an IgG subclass induced by type 2 cytokines such as IL-4 and IL-13, we sought to characterize and compare local IgG4 expression in patients with and without EOM. Methods: Twelve patients with bilateral profound hearing loss, 9 of which underwent a cochlear implant surgery, were enrolled in this study (6 with EOM and 6 without EOM). The surgical specimens were harvested during surgery and were subjected to IgG4 immunostaining. Result: The middle ear mucosa showed the presence of a large number of IgG4-positive cells in patients with EOM, which was significantly higher than that in patients without EOM. Conclusion: Local IgG4 expression was observed in patients with EOM in comparison to those without EOM, suggesting that IgG4 contributes to EOM pathogenesis.

show abstract

“…Antigen-specific serum IgE is high in allergic rhinitis patients, and other antigenspecific antibodies such as IgG, IgG4 and IgA have been investigated recently. Serum and salivary IgG4 is reported to be lower in allergic patients than in non-allergic patients [15], although some other reports showed that antigen-specific serum IgG4 is higher in allergic rhinitis or eosinophilic chronic rhinosinusitis [16,17]. On the other hand, serum, bronchial secretary and salivary IgA is reported to be lower in allergic patients than in non-allergic patients [15,18,19].…”

Section: Biomarkers For Monitoring the Efficacy Of Slitmentioning

confidence: 98%

Relationship between Saliva and Sublingual Immunotherapy

Oka

Okano

2021

Pathogens

Self Cite

View full text Add to dashboard Cite

The demand for allergen specific immunotherapy (AIT), especially sublingual immunotherapy (SLIT), is increasing because of its efficacy in inducing clinical remission of allergic diseases and its low risk of side effects. Since not all patients that undergo SLIT demonstrate an improvement in allergic symptoms, the development of biomarkers to predict the outcome and adjuvants for SLIT is desired. Saliva is the first target with which tablets used in SLIT come into contact, and salivary pH, chemical properties or microbiome composition are reported to possibly be associated with the outcome of SLIT. Antibodies such as IgG4 and IgA not only in the serum but also in the saliva are increased after SLIT and may also be associated with the efficacy of SLIT. The development of the metagenomic sequencing technique makes it possible to determine the microbiome composition and ratio of each bacterium, and researchers can investigate the relationships between specific bacteria and the immune response. Some bacteria are reported to improve the SLIT outcome and have the potential to be used as biomarkers for the selection of patients and as adjuvants in SLIT. Here, we introduce biomarkers for SLIT and present recent findings regarding the relationship between saliva and SLIT.

show abstract

Serum IgG4 as a biomarker reflecting pathophysiology and post-operative recurrence in chronic rhinosinusitis

Cited by 16 publications

References 20 publications

Developments and Emerging Trends in the Global Treatment of Chronic Rhinosinusitis From 2001 to 2020: A Systematic Bibliometric Analysis

Developments and Emerging Trends in the Global Treatment of Chronic Rhinosinusitis From 2001 to 2020: A Systematic Bibliometric Analysis

IgG4 Expression in Patients with Eosinophilic Otitis Media

Relationship between Saliva and Sublingual Immunotherapy

Contact Info

Product

Resources

About